* Greenwich Lifesciences Inc GLSI.OQ GLSI.O is expected
to show no change in quarterly revenue when it reports
results on May 22 (estimated) for the period ending March
31 2024
*
* LSEG's mean analyst estimate for Greenwich Lifesciences
Inc is
for a loss of 20 cents per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for
the pharmaceuticals
peer group is also "Buy".
* Wall Street's median 12-month price target for Greenwich
Lifesciences Inc is $36.00, above its last closing price
of $13.98.
This summary was machine generated May 20 at 20:02 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)